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In this issue…
The new drugs reviewed in this issue have all been
assessed for safety and efficacy. Although a treatment
may be efficacious, John Marley points out that it may
not be effective or efficient.
Heart failure needs effective treatment, but there are
often difficulties in managing the condition. Henry
Krum suggests some solutions to these therapeutic
dilemmas. Peter Fletcher believes that beta blockers are
the solution for some patients, even though these drugs
were once contraindicated in heart failure.
While the cost-effectiveness of bisphosphonates may be
questioned, they do have a role in some patients with low
bone density, particularly postmenopausal women.
John Martin and Vivian Grill inform us how the drugs
work, while Peter Ebeling discusses their clinical use in
osteoporosis.
The most effective treatment may not be a drug. In his
article on panic disorder John Tiller tells us that cognitive
behaviour therapy helps many patients.  One of these
patients is actor Garry McDonald who reveals how he
overcame his anxiety.
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How is it, that guidelines for treatment often seem unrelated
to the patient sitting in front of the doctor? Guidelines are
mostly based on evidence gathered from randomised controlled
trials. These trials are very good at assessing efficacy – that is,
can a treatment work? Despite this, trials are not without
substantial biases. Many people may be screened before a few
are chosen to be included in a study, yet the results of the study
will be applied to the very people who were excluded. The
population studied in trials tends to be young, male, white,
suffering from a single condition and using a single treatment.
Most patients, at least in general practice, do not fit this
description. They often have multiple illnesses, take multiple
medications and are either too young or too old to have been
included in clinical trials. Perhaps we should accept a proposal
to define efficacy in relation to medications as ‘the extent to
which a drug has the ability to bring about its intended effect
under ideal circumstances, such as in a randomised clinical
trial’.*
Efficacy is not the same as effectiveness.1 A treatment is
effective if it works in real life in non-ideal circumstances. In
real life, medications will be used in doses and frequencies
never studied and in patient groups never assessed in the trials.
Drugs will be used in combination with other medications that
have not been tested for interactions, and by people other
than the patient – the ‘over the garden fence’ syndrome.
Effectiveness cannot be measured in controlled trials, because
the act of inclusion into a study is a distortion of usual practice.
Effectiveness can be defined as ‘the extent to which a drug
achieves its intended effect in the usual clinical setting’.* It
can be evaluated through observational studies of real practice.
This allows practice to be assessed in qualitative as well as
quantitative terms.2
Australia is well suited to conduct observational studies because
we have a high standard of relatively unrestricted practice and
good national databases, such as those held by the Health
Insurance Commission. These databases can be used for
validating researchers’ separate database effectiveness
studies. In America there are very large patient databases
held by the Health Maintenance Organisations. Their size is
impressive, but size is not everything. The data may have been
collected primarily for billing and they may be incomplete.
Clinical practice is often governed by protocols, and
medications are limited to those supplied by the current
preferred providers. The reimbursement mechanism for doctors
may mean that they code conditions at the highest severity
level. Patients belonging to one of these organisations may not
represent the American population as a whole. In Britain, the
General Practice Research Database, compiled from practice
electronic records, is very useful, especially for studies in
pharmacoepidemiology. The British enjoy relatively
unrestricted clinical practice, but they do not have readily
usable national datasets against which to check the validity
of their database studies.
It is an irony that drugs are licensed for use almost exclusively
on the results of controlled trials, yet they are withdrawn from
use because of observational data that would not be acceptable
to licensing authorities. Biases are present in observational
studies, just as they are in trials, but they can be defined and
often controlled for, giving these studies a much greater value
than that currently awarded to them.
* From a suggested dictionary of pharmacoepidemiology by
C. Ineke Neutel, University of Ottawa Institute on Health of
the Elderly, Research Department, SCO Health Services.
43 Bruyere Street, Ottawa CANADA K1N 5C8.
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Efficiency depends on whether a drug is worth its cost to
individuals or society. The most efficacious treatment, based
on the best evidence, may not be the most cost-effective
option. It may not be acceptable to patients. In every country,
rationing of health care is a reality. There is no country,
however wealthy, that can afford to deliver all the health care
possible to the whole of its population at all times. Rationing
may be implicit or explicit, but it will happen. Good
effectiveness and efficiency studies will make this rationing
more informed.
Good practical guidelines, such as the Therapeutic Guidelines
series, are clearly very important and extremely useful. They
could be made even more relevant to the patient in front of the
doctor, by being less dependent on efficacy studies. We should
make more use of effectiveness and efficiency studies and
abandon the censorship of the evidence drawn from them.
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Prescribing by numbers
Editor, – It was interesting to see an article on the number
needed to treat (NNT) (Aust Prescr 2000;23:38). NNT is
better than looking at relative risk reductions but NNT still
does not always give you a feel for the relevance of an
intervention.
I believe clinical decision-making needs to consider two
numbers. These are the paired absolute incidences.
X = Event rate control (the outcome with placebo,
or the outcome if you do nothing)
Y = Event rate active (the outcome with treatment)
Consider a room full of 100 people with a clinical problem.
Put it to them, ‘Do nothing and the event will happen to X of
you, and if all of you take the pill it will happen to Y of you.’
Using the Helsinki Heart study as quoted in the article, how
would 100 men respond if told ‘Take gemfibrozil for five
years and 4.1 of you will have an event, do nothing and
2.7 of you will have an event’? I suspect many would say why
bother with treatment, but some would say OK.
Clinical decision-making needs to be made in the context of
real people. Other comorbidity, patient attitude, patient
expectations, the psychological burden of disease label,
adverse effects, secondary costs (for example, more visits to
the doctor) all need consideration. I believe that by looking
at the two numbers (X and Y) I can get a better feel for the
relevance of an intervention, and also inform my patients
about ‘doing something’ versus ‘doing nothing’.
I believe the treatment of risk and risk factors is greatly
overrated, and that many are treated for risk without a
genuine consideration of how much of a difference it could
make for the individual. As the surgeons learn to withhold
the knife, I believe we should learn to hold back the drug
treatment of risk factors, not because there is no evidence, but
because in the bigger picture it is irrelevant to the patient –




Medicines and the media
Editor, – The Australian Prescriber editorial (Aust Prescr
2000;23:70–1) regarding reporting of medicines in the media
is timely. On 13 April 2000, an article in the Adelaide
‘Advertiser’ included the headline ‘Accepted safe levels of
cholesterol “still too high”’ and pictured a young woman
having a cholesterol test. The commentary continued,
‘Worldwide evidence proved “normal” cholesterol levels in
healthy men and women were too high, an international
authority on heart disease said in Adelaide yesterday’. The
article went on to talk about ‘...a new ultra-low dose
cholesterol-reducing drug called cerivastatin, ...recently
approved for use in Australia...’
Assuming a new study had been released assessing health
outcomes associated with cerivastatin, we contacted the
reporter. He could not provide any information to support
the story, but suggested we contact the Adelaide marketing
company publicising the visit of the overseas specialist. The
marketing company supplied their media release, but could
not provide a reference. They reported the media release was
redrafted from one produced by a Sydney company. The
Sydney marketing company also could not provide a
reference. They said their media release was based on
information supplied by Bayer, but they had returned all
material to Bayer.
We rang Bayer on five occasions. The product manager was
never available to speak to us, nor has he returned our call.
The Adelaide marketing company, however, was more
sympathetic. They rang us back to say the West of Scotland
Coronary Prevention Study, a 1995 study involving
pravastatin, was the basis for the story. Was the story ‘news’
or advertising? How can consumers tell the difference?
Libby Roughead and
Andrew Gilbert
School of Pharmacy and Medical Sciences
University of South Australia
Adelaide
